Purple Biotech (NASDAQ:PPBT) posted a net loss of $26.4 million for the full year 2025, a result heavily impacted by a $20.5 million non-cash impairment of its CM24 and NT219 programs.
Xenetic Biosciences (NASDAQ:XBIO) reported a 19% increase in royalty revenue for the full year 2025, providing a financial cushion as the company moves closer to human clinical trials for its lead immuno-oncology program.
bioAffinity Technologies (NASDAQ:BIAF) reported fiscal year 2025 results that underscore an aggressive transition from a broad laboratory service model to a specialized, high-growth diagnostic powerhouse focused on early-stage lung cancer detection.
Savara (NASDAQ:SVRA) provided a year-end financial update that underscores the company’s transition toward the commercial stage, with increased spending on pre-launch activities for its lead drug candidate, molgramostim.
Kestrel Group (NASDAQ:KG) delivered a bifurcated set of results for its fiscal year ended December 31, 2025, characterized by a massive surge in its fee-based business and a heavy fourth-quarter net loss due to specific one-time accounting charges.
Acurx Pharmaceuticals (NASDAQ:ACXP) on Friday reported a full-year 2025 net loss of $8 million, with cash and cash equivalents of $7.6 million as of December 31, 2025, supported by approximately $4 million in gross proceeds from its equity line of credit during the year.
AC Immune (NASDAQ:ACIU) unveiled clinical data on Friday suggesting its experimental vaccine could potentially slow the progression of Parkinson’s disease, a milestone that accompanied a significant corporate restructuring aimed at preserving its capital.
The ONE Group Hospitality (NASDAQ:STKS) reported a complex fourth quarter for fiscal 2025, marked by a strategic contraction of its portfolio and a calendar shift that dampened its traditional holiday revenue peak.
Better Home & Finance Holding Company (NASDAQ:BETR) delivered a sharp increase in operational momentum for the fourth quarter of 2025, signaling that its AI-native mortgage platform is beginning to capture significant market share as the interest rate environment shifts.
Douglas Elliman (NYSE:DOUG) turned a corner in fiscal 2025, moving from a steep loss to a net profit.
Waldencast (NASDAQ:WALD) reported a transformative finish to fiscal year 2025, prioritizing balance sheet stability through a series of strategic divestitures and debt restructurings while navigating mixed performance across its core brand portfolio.
The Buckle (NYSE:BKE) delivered a solid conclusion to its 2025 fiscal year, posting gains in both top-line revenue and net income as the denim-focused retailer continues to navigate a shifting consumer landscape.
